New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 12, 2021 - Sanofi announced the FDA approval of Fabrazyme (agalsidase beta), for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
Download PDF
Return to publications
